Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.

Gynecologic Oncology
Halla S NimeiriCalifornia Phase II Consortium

Abstract

The objectives of this phase II trial were to assess the activity and tolerability of the combination of bevacizumab and erlotinib in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer. This was a single arm, multicenter phase II trial with overall objective response as the primary endpoint. Eligible patients had two or fewer prior chemotherapy regimens for recurrent or refractory disease and no prior anti-VEGF or anti-EGFR agents. Bevacizumab, 15 mg/kg, was administered intravenously every 21 days and erlotinib, 150 mg orally, was given daily. Between July and October 2005, 13 patients were enrolled. There were two major objective responses, one complete response of 16+ month duration and one partial response of 11 month duration, for a response rate of 15% (95% CI 1.9% to 45.4%). Seven patients had a best response of stable disease. The most common grade 3 or 4 toxicities included anemia (n=1), nausea (n=2), vomiting (n=1), hypertension (n=1), and diarrhea (n=2). One patient with an ileostomy was removed from the study secondary to grade 3 diarrhea. Two patients had fatal gastrointestinal perforations. There was no strong suggestion that this combination was superior to single agent bevacizumab, and ...Continue Reading

Citations

Sep 25, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Alfonso Sánchez-MuñozAntonio González-Martín
Dec 17, 2009·British Journal of Cancer·N MurukeshG C Jayson
Feb 5, 2010·Journal of Oncology·Lyndsay J Willmott, John P Fruehauf
Jan 30, 2010·Journal of Oncology·Nicanor I Barrena MedelThomas J Herzog
May 4, 2011·World Journal of Biological Chemistry·Hiroaki Itamochi
May 10, 2011·American Journal of Clinical Oncology·Don S Dizon
Jan 12, 2012·Clinical & Developmental Immunology·Filippo BellatiMarianna Nuti
Dec 6, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Karina Dahl SteffensenAnders Jakobsen
Jan 5, 2013·Current Treatment Options in Oncology·Ernest S HanLucille Leong
Sep 28, 2013·Expert Opinion on Investigational Drugs·Umberto Leone Roberti MaggioreSimone Ferrero
Nov 3, 2010·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Terence C ChuaDavid L Morris
Jan 9, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Helen J Mackay, Amit M Oza
Mar 16, 2012·Future Medicinal Chemistry·Jason A WilkenNita J Maihle
Sep 18, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Stephen A WelchAmit M Oza
Jul 3, 2013·Expert Opinion on Investigational Drugs·Matteo MorottiSimone Ferrero
Mar 24, 2012·Expert Opinion on Therapeutic Targets·Millie Das, Heather Wakelee
Sep 6, 2014·Expert Review of Anticancer Therapy·Ajit GubbiNeil J Finkler
Nov 10, 2016·Expert Review of Molecular Diagnostics·Rebecca A PrevisShannon N Westin
Oct 16, 2018·The Cochrane Database of Systematic Reviews·Jo MorrisonAndrew Bryant
Jan 7, 2009·Current Opinion in Obstetrics & Gynecology·Fiona Collinson, Gordon Jayson
May 20, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Stacy S ShordAmina George
Jul 14, 2009·The Oncologist·Susana Banerjee, Martin Gore
Jan 14, 2010·Journal of Oncology·Susana M Campos, Sue Ghosh
Jun 21, 2013·Expert Opinion on Investigational Drugs·Xia-wei WeiYu-Quan Wei
Oct 7, 2011·The Cochrane Database of Systematic Reviews·Krishnayan HaldarJo Morrison
May 30, 2012·Oncology Reports·Hiroshi ShigetomiHiroshi Kobayashi
Mar 15, 2014·International Journal of Oncology·Vincenza ConteducaUgo De Giorgi
Aug 4, 2016·Cancer Investigation·Ioannis Ntanasis-StathopoulosElias A Kotteas
Jun 5, 2012·Investigational New Drugs·Shannon N WestinRobert L Coleman
Apr 22, 2009·Current Treatment Options in Oncology·Ernest S HanMark Wakabayashi
Feb 18, 2011·Future Oncology·Ursula A Matulonis
Feb 25, 2009·Nature Reviews. Cancer·Timothy A YapStan B Kaye
Jul 5, 2012·Women's Health·Ashley Stuckey, Don S Dizon
Jan 15, 2010·Journal of Oncology·Francois P Duhoux, Jean-Pascal Machiels
Jan 1, 2010·Cancers·Emma DeanJurjees Hasan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.